Nebulized Mucoregulators Show No Benefit in Ventilated Acute Respiratory Failure
Start here
A randomized trial in 1,956 mechanically ventilated patients with acute respiratory failure found that adding nebulized carbocisteine, a mucoregulator, or hypertonic saline to usual care provided no benefit and showed possible harm, prompting calls for caution with mucoactive drugs in this setting. The findings appear alongside other notable results: an 840-child trial of five days of azithromycin for moderate-to-severe wheeze in children aged 18–59 months was stopped early for futility, and a phase 3 trial of sunvozertinib in 324 patients adds first-line data in EGFR exon 20 insertion advanced NSCLC following its accelerated approval after chemotherapy. A review of classic myeloproliferative neoplasms, driven by acquired JAK2, CALR and MPL mutations, highlights symptomatic control as the mainstay, with some disease modification from peg-IFNα and JAK2 inhibitors. How clinicians will adjust use of mucoactive agents in the ICU remains open.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- YouTubePickNEJM This Week (2026-08-20): Mucoregulators in Acute Respiratory Failure, Childhood Wheeze, First-line EGFR ex20ins NSCLC, and Myeloproliferative Neoplasms
In 1,956 mechanically ventilated acute respiratory failure patients, adding nebulized carbocisteine (a mucoregulator) or hypertonic saline to usual care showed no benefit and possible harm, prompting calls for caution with mucoactive drugs. An 840-child RCT of azithromycin for 5 days in moderate-to-severe wheeze (18–59 months) was stopped early for futility, and a phase 3 trial adds first-line data on sunvozertinib (324 patients) in EGFR ex20ins advanced NSCLC after its accelerated approval post-chemotherapy. A review covers classic myeloproliferative neoplasms (ET/PV/PMF), driven by acquired JAK2/CALR/MPL mutations, with symptomatic control as mainstay and some disease modification from peg-IFNα and JAK2 inhibitors, plus a Perspective on LLM-driven AI copilots.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.